

【4-9 メタアナリシス】

<b>CQ</b>		HER2陰性転移・再発乳癌に対する化学療法に分子標的治療薬を併用することは推奨されるか？																																																																				
<b>P</b>	HER2陰性転移・再発乳癌(女性)	<b>I</b>	分子標的治療薬(ペバシズマブ)+化学療法																																																																			
<b>C</b>	化学療法	<b>O</b>	ORR																																																																			
<b>研究デザイン</b>	RCT	<b>文献数</b>	7	<b>コード</b>	Miller 2007 (E2100), Miles 2010 (AVADO), Martin 2011, Robert 2011 (RIBBON-1 Cape cohort), Robert 2011 (RIBBON-1 T+Anthra cohort), Miller 2005 (AVF2119g), Brufsky 2011 (RIBBON-2), Minckwitz 2014 (TANIA)																																																																	
<b>モデル</b>	Random Effects	<b>方法</b>	Mantel-Haenszel method (RevMan5.3)																																																																			
<b>効果指標</b>	Risk Ratio	<b>統合値</b>	1.47 ( 1.26 - 1.71 ) P< 0.00001																																																																			
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Beva+CTx Events Total</th> <th>CTx Events Total</th> <th>Weight</th> <th>Risk Ratio M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Brufsky 2011 (RIBBON-2)</td> <td>143 362</td> <td>53 179</td> <td>13.9%</td> <td>1.33 [1.03, 1.73]</td> </tr> <tr> <td>Martin 2011</td> <td>50 97</td> <td>39 94</td> <td>11.9%</td> <td>1.24 [0.81, 1.69]</td> </tr> <tr> <td>Miles 2010 (AVADO)</td> <td>243 407</td> <td>96 207</td> <td>18.3%</td> <td>1.29 [1.09, 1.52]</td> </tr> <tr> <td>Miller 2005 (AVF2119g)</td> <td>46 232</td> <td>21 230</td> <td>6.9%</td> <td>2.17 [1.34, 3.52]</td> </tr> <tr> <td>Miller 2007 (E2100)</td> <td>112 229</td> <td>54 243</td> <td>13.4%</td> <td>2.20 [1.68, 2.88]</td> </tr> <tr> <td>Minckwitz 2014 (TANIA)</td> <td>38 182</td> <td>31 185</td> <td>8.1%</td> <td>1.25 [0.81, 1.91]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 Cape cohort)</td> <td>115 325</td> <td>38 161</td> <td>11.6%</td> <td>1.50 [1.09, 2.05]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 T+Anthra cohort)</td> <td>177 345</td> <td>67 177</td> <td>15.9%</td> <td>1.36 [1.09, 1.68]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td><b>2179</b></td> <td><b>1476</b></td> <td><b>100.0%</b></td> <td><b>1.47 [1.26, 1.71]</b></td> </tr> <tr> <td colspan="5">Total events: 924 399</td> </tr> <tr> <td colspan="5">Heterogeneity: Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 16.21, df = 7 (P = 0.02); I<sup>2</sup> = 57%</td> </tr> <tr> <td colspan="5">Test for overall effect: Z = 5.00 (P &lt; 0.00001)</td> </tr> </tbody> </table>					Study or Subgroup	Beva+CTx Events Total	CTx Events Total	Weight	Risk Ratio M-H, Random, 95% CI	Brufsky 2011 (RIBBON-2)	143 362	53 179	13.9%	1.33 [1.03, 1.73]	Martin 2011	50 97	39 94	11.9%	1.24 [0.81, 1.69]	Miles 2010 (AVADO)	243 407	96 207	18.3%	1.29 [1.09, 1.52]	Miller 2005 (AVF2119g)	46 232	21 230	6.9%	2.17 [1.34, 3.52]	Miller 2007 (E2100)	112 229	54 243	13.4%	2.20 [1.68, 2.88]	Minckwitz 2014 (TANIA)	38 182	31 185	8.1%	1.25 [0.81, 1.91]	Robert 2011 (RIBBON-1 Cape cohort)	115 325	38 161	11.6%	1.50 [1.09, 2.05]	Robert 2011 (RIBBON-1 T+Anthra cohort)	177 345	67 177	15.9%	1.36 [1.09, 1.68]	<b>Total (95% CI)</b>	<b>2179</b>	<b>1476</b>	<b>100.0%</b>	<b>1.47 [1.26, 1.71]</b>	Total events: 924 399					Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 16.21, df = 7 (P = 0.02); I <sup>2</sup> = 57%					Test for overall effect: Z = 5.00 (P < 0.00001)				
Study or Subgroup	Beva+CTx Events Total	CTx Events Total	Weight	Risk Ratio M-H, Random, 95% CI																																																																		
Brufsky 2011 (RIBBON-2)	143 362	53 179	13.9%	1.33 [1.03, 1.73]																																																																		
Martin 2011	50 97	39 94	11.9%	1.24 [0.81, 1.69]																																																																		
Miles 2010 (AVADO)	243 407	96 207	18.3%	1.29 [1.09, 1.52]																																																																		
Miller 2005 (AVF2119g)	46 232	21 230	6.9%	2.17 [1.34, 3.52]																																																																		
Miller 2007 (E2100)	112 229	54 243	13.4%	2.20 [1.68, 2.88]																																																																		
Minckwitz 2014 (TANIA)	38 182	31 185	8.1%	1.25 [0.81, 1.91]																																																																		
Robert 2011 (RIBBON-1 Cape cohort)	115 325	38 161	11.6%	1.50 [1.09, 2.05]																																																																		
Robert 2011 (RIBBON-1 T+Anthra cohort)	177 345	67 177	15.9%	1.36 [1.09, 1.68]																																																																		
<b>Total (95% CI)</b>	<b>2179</b>	<b>1476</b>	<b>100.0%</b>	<b>1.47 [1.26, 1.71]</b>																																																																		
Total events: 924 399																																																																						
Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 16.21, df = 7 (P = 0.02); I <sup>2</sup> = 57%																																																																						
Test for overall effect: Z = 5.00 (P < 0.00001)																																																																						
	コメント: Beva群で有意にORR良好。異質性ありの判定であるが、全体の傾向は同じでありこのSRをそのまま採用。																																																																					
<b>Funnel plot</b>																																																																						
	コメント:																																																																					
<b>その他の解析</b>	施行せず				コメント:																																																																	
メタリグレッション																																																																						
感度分析																																																																						